Edgewise Therapeutics, Inc. Interest Income, Other
Edgewise Therapeutics, Inc. (EWTX) reported Interest Income, Other of $4.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeOther · last filed 2026-08-06
- Edgewise Therapeutics, Inc. interest income, other for the quarter ending 2026-06-30 was $4.62M, a 28.93% decline year-over-year.
- Edgewise Therapeutics, Inc. interest income, other for the quarter ending 2026-03-31 was $5.10M, a 1.14% decline year-over-year.
- Edgewise Therapeutics, Inc. interest income, other for the quarter ending 2025-12-31 was $5.76M, a 1.96% decline year-over-year.
- Edgewise Therapeutics, Inc. interest income, other for the quarter ending 2025-09-30 was $6.19M, a 1.76% decline year-over-year.
- Edgewise Therapeutics, Inc. interest income, other for fiscal 2025 was $23.61M, a 5.63% decline from fiscal 2024.
- Edgewise Therapeutics, Inc. interest income, other for fiscal 2024 was $25.02M, a 76.26% increase from fiscal 2023.
- Edgewise Therapeutics, Inc. interest income, other for fiscal 2023 was $14.19M, a 253.26% increase from fiscal 2022.
- Edgewise Therapeutics, Inc. interest income, other for fiscal 2022 was $4.02M, a 899.50% increase from fiscal 2021.
| Period end | Interest Income, Other 3 month | Interest Income, Other 6 month | Interest Income, Other 9 month | Interest Income, Other 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.62M 10-Q · filed 2026-08-06 | $9.72M 10-Q · filed 2026-08-06 | $15.48M derived: sum of 3 quarters · filed 2026-08-06 | $21.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.10M 10-Q · filed 2026-05-07 | $10.87M derived: sum of 2 quarters · filed 2026-05-07 | $17.06M derived: sum of 3 quarters · filed 2026-05-07 | $23.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.96M derived: sum of 2 quarters · filed 2026-02-26 | $18.45M derived: sum of 3 quarters · filed 2026-08-06 | $23.61M 10-K · filed 2026-02-26 |
| 2025-09-30 | $6.19M 10-Q · filed 2025-11-06 | $12.69M derived: sum of 2 quarters · filed 2026-08-06 | $17.85M 10-Q · filed 2025-11-06 | $23.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.50M 10-Q · filed 2026-08-06 | $11.66M 10-Q · filed 2026-08-06 | $17.53M derived: sum of 3 quarters · filed 2026-08-06 | $23.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.16M 10-Q · filed 2026-05-07 | $11.04M derived: sum of 2 quarters · filed 2026-05-07 | $17.34M derived: sum of 3 quarters · filed 2026-05-07 | $23.95M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.18M derived: sum of 2 quarters · filed 2026-02-26 | $18.79M derived: sum of 3 quarters · filed 2026-02-26 | $25.02M 10-K · filed 2026-02-26 |
| 2024-09-30 | $6.30M 10-Q · filed 2025-11-06 | $12.91M derived: sum of 2 quarters · filed 2025-11-06 | $19.14M 10-Q · filed 2025-11-06 | $22.86M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $6.61M 10-Q · filed 2025-08-07 | $12.84M 10-Q · filed 2025-08-07 | $16.56M derived: sum of 3 quarters · filed 2026-02-26 | $20.30M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $6.23M 10-Q · filed 2025-05-08 | $9.95M derived: sum of 2 quarters · filed 2026-02-26 | $13.69M derived: sum of 3 quarters · filed 2026-02-26 | $17.56M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.46M derived: sum of 2 quarters · filed 2026-02-26 | $11.33M derived: sum of 3 quarters · filed 2026-02-26 | $14.19M 10-K · filed 2026-02-26 |
| 2023-09-30 | $3.74M 10-Q · filed 2024-11-07 | $7.61M derived: sum of 2 quarters · filed 2024-11-07 | $10.47M 10-Q · filed 2024-11-07 | $13.14M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.87M 10-Q · filed 2024-08-08 | $6.74M 10-Q · filed 2024-08-08 | $9.40M derived: sum of 3 quarters · filed 2024-08-08 | $10.16M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.87M 10-Q · filed 2024-05-09 | $5.53M derived: sum of 2 quarters · filed 2024-05-09 | $6.29M derived: sum of 3 quarters · filed 2024-05-09 | $6.72M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $3.43M derived: sum of 2 quarters · filed 2024-02-22 | $3.85M derived: sum of 3 quarters · filed 2024-02-22 | $4.02M 10-K · filed 2024-02-22 |
| 2022-09-30 | $764.00K 10-Q · filed 2023-11-09 | $1.19M derived: sum of 2 quarters · filed 2023-11-09 | $1.35M 10-Q · filed 2023-11-09 | $1.48M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $424.00K 10-Q · filed 2023-08-10 | $590.00K 10-Q · filed 2023-08-10 | $716.00K derived: sum of 3 quarters · filed 2023-08-10 | $843.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $166.00K 10-Q · filed 2023-05-11 | $292.00K derived: sum of 2 quarters · filed 2023-05-11 | $419.00K derived: sum of 3 quarters · filed 2023-05-11 | $526.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $253.00K derived: sum of 2 quarters · filed 2023-02-23 | $360.00K derived: sum of 3 quarters · filed 2023-02-23 | $402.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | $127.00K 10-Q · filed 2022-11-03 | $234.00K derived: sum of 2 quarters · filed 2022-11-03 | $276.00K 10-Q · filed 2022-11-03 | $278.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $107.00K 10-Q · filed 2022-08-04 | $149.00K 10-Q · filed 2022-08-04 | $151.00K derived: sum of 3 quarters · filed 2022-08-04 | $152.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $42.00K 10-Q · filed 2022-05-11 | $44.00K derived: sum of 2 quarters · filed 2022-05-11 | $45.00K derived: sum of 3 quarters · filed 2022-05-11 | $48.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $3.00K derived: sum of 2 quarters · filed 2022-02-24 | $6.00K derived: sum of 3 quarters · filed 2022-02-24 | $69.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $1.00K 10-Q · filed 2021-11-10 | $4.00K derived: sum of 2 quarters · filed 2021-11-10 | $67.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.00K 10-Q · filed 2021-08-09 | $66.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $63.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |